Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20432638 | 1.00 | HDAC6 (0.58) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL20420898 | 0.90 | CACNA1G (0.48) | HDAC6HDAC1MEN1POLBKMT2A | |
| SCHEMBL17078523 | 0.88 | HDAC1 (0.57) | HDAC6HDAC1HDAC8HDAC10HDAC3 | |
| SCHEMBL17078692 | 0.87 | CA1 (0.47) | MEN1POLBKMT2A | |
| SCHEMBL17078735 | 0.86 | HDAC1 (0.58) | HDAC6HDAC1HDAC8 | |
| SCHEMBL20432735 | 0.85 | HDAC1 (0.59) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL17078474 | 0.85 | HDAC1 (0.59) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL17078445 | 0.85 | HDAC6 (0.60) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL17078904 | 0.84 | HDAC1 (0.59) | HDAC6HDAC1HDAC8HDAC2HDAC10 | |
| SCHEMBL17078727 | 0.83 | HDAC6 (0.79) | HDAC6HDAC1HDAC8HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008414-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-01-13 | — | — | US | claimed |
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-14 | — | — | US | claimed |
| EP-3116859-B1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-08-01 | — | — | EP | claimed |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-06 | — | — | US | claimed |
| US-20220008414-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-01-13 | — | — | US | disclosed |
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-14 | — | — | US | disclosed |
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-14 | — | — | US | disclosed |
| EP-3116859-B1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-08-01 | — | — | EP | disclosed |
| EP-3116859-B1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-08-01 | — | — | EP | disclosed |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-06 | — | — | US | disclosed |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-06 | — | — | US | disclosed |
| EP-3116859-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015137750-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015137750-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC1 2/4885HDAC8 11/4885 |
| US-20220008414-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885HDAC1 2/4885HDAC8 11/4885 |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC1 2/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.